Idera Pharmaceuticals Reports Second Quarter 2011 financial Results MarketWatch (press release) In our autoimmune unwellness program, we are reviewing the FDA comments connected a Phase 2 rule that we recently submitted for evaluating IMO-3100 in patients with psoriasis , and are assessing our next steps for nonindustrial IMO-3100 in psoriasis ," commented ... and more » Link To Article
No comments:
Post a Comment